retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and Safety of in the Treatment of and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis New clinical trial results show

Tirzepatide has shown slightly higher average weight loss in head-to-head trials, but it's also typically more expensive and may have a different side effect profile

If you are a Kaiser member, start with your PCP, get into the weight management program, and be proactive about documentation

The frequency changes across the three phases

A licensed treatment is different from an unregulated online product because it has been reviewed for quality, safety and effectiveness

In clinical trials of semaglutide injection for weight management, acute kidney injury occurred in 7 patients (0.4 cases per 100 patient-years) receiving semaglutide vs

TRIUMPH-3 -- Cardiovascular Disease Population -- RESULTS (Jul 2026) TRIUMPH-3 tested retatrutide in the highest-risk weight-management population studied so far: adults with severe obesity (average BMI 40.4 kg/m2, average weight 111.4 kg) who already have established cardiovascular disease